Nykode Therapeutics ASA announced that all patients in 6 mg and 9 mg dose groups showed HPV16‑specific immune responses in VB‑C‑03 trial.
The immune responses were rapid in onset and remained durable through the entire treatment period.
The trial achieved a confirmed objective response rate of 38.5% across participants.
Results were disclosed via Reuters on 20‑Apr‑2026, with NYKD shares rising 11.64%.